市中感染(Community-Acquired Infections):世界の治験レビュー(2014年下半期版)

◆英語タイトル:Community-Acquired Infections Global Clinical Trials Review, H2, 2014
◆商品コード:GDHC2442CTIDB
◆発行会社(リサーチ会社):GlobalData
◆発行日:2014年11月30日
◆ページ数:73
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥780,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における市中感染(Community-Acquired Infections) 治療の臨床試験動向について調査・分析し、アジア太平洋/欧州/北米/中南米の主要国における治験件数、段階(フェーズ)別の治験件数、進捗状況別の治験件数、治験目標の達成状況、有望な薬剤、治験関連の最新ニュース、代表的な企業・大学・研究機関における治験概要、代表的な治験のプロファイルなどのデータをまとめてお届けいたします。

・イントロダクション
  - 市中感染(Community-Acquired Infections)
  - 当レポートの概要
・市中感染(Community-Acquired Infections):各地域別治験状況
  - 各国の治験件数及び平均被験者数
   アジア太平洋の主要国における治験件数
   欧州の主要国における治験件数
   北米の主要国における治験件数
   中東・アフリカの主要国における治験件数
   中南米の主要国における治験件数
・G7諸国での治験件数
・G7諸国での治験件数:段階別
・G7諸国での治験件数:進捗状況別
・段階(フェーズ)別の治験件数:進行中の治験(段階別)
・進捗状況別の治験件数
・治験目標の達成状況
・未完了の治験件数
・一定期間に採用された被験者
・スポンサーの種類別治験件数
・有望なスポンサー
・有望な薬剤
・治験のプロファイル
  - 代表的な企業における治験概要
  - 代表的な大学・研究機関における治験概要
・5つの代表的な治験のプロファイル
【レポートの概要】

Community-Acquired Infections Global Clinical Trials Review, H2, 2014

Summary

GlobalData’s clinical trial report, “Community-Acquired Infections Global Clinical Trials Review, H2, 2014″ provides data on the Community-Acquired Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Community-Acquired Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Community-Acquired Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Community-Acquired Infections 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Community-Acquired Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Community-Acquired Infections to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Community-Acquired Infections 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Community-Acquired Infections Therapeutics Clinical Trials 30
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
GlaxoSmithKline plc 32
Clinical Trial Overview of GlaxoSmithKline plc 32
Pfizer Inc. 33
Clinical Trial Overview of Pfizer Inc. 33
Panacea Biotec Limited 34
Clinical Trial Overview of Panacea Biotec Limited 34
Daiichi Sankyo Company, Limited 35
Clinical Trial Overview of Daiichi Sankyo Company, Limited 35
Tetraphase Pharmaceuticals Inc. 36
Clinical Trial Overview of Tetraphase Pharmaceuticals Inc. 36
TaiGen Biopharmaceuticals Holdings Limited 37
Clinical Trial Overview of TaiGen Biopharmaceuticals Holdings Limited 37
Janssen Research & Development, LLC 38
Clinical Trial Overview of Janssen Research & Development, LLC 38
Dong Wha Pharma Co., Ltd. 39
Clinical Trial Overview of Dong Wha Pharma Co., Ltd. 39
Cubist Pharmaceuticals, Inc. 40
Clinical Trial Overview of Cubist Pharmaceuticals, Inc. 40
Belpharma S.A. 41
Clinical Trial Overview of Belpharma S.A. 41
Clinical Trial Overview of Top Institutes / Government 42
Hanyang University Medical Center 42
Clinical Trial Overview of Hanyang University Medical Center 42
Ewha Womans University 43
Clinical Trial Overview of Ewha Womans University 43
Kyungpook National University 44
Clinical Trial Overview of Kyungpook National University 44
Katholieke Universiteit Leuven 45
Clinical Trial Overview of Katholieke Universiteit Leuven 45
Rennes University Hospital 46
Clinical Trial Overview of Rennes University Hospital 46
University of Milan 47
Clinical Trial Overview of University of Milan 47
Five Key Clinical Profiles 48
Appendix 71
Abbreviations 71
Definitions 71
Research Methodology 72
Secondary Research 72
About GlobalData 73
Contact Us 73
Disclaimer 73
Source 73

List of Tables
Community-Acquired Infections Therapeutics, Global, Clinical Trials by Region, 2014* 7
Community-Acquired Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Community-Acquired Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Community-Acquired Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Community-Acquired Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Community-Acquired Infections Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Community-Acquired Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Community-Acquired Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Community-Acquired Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Community-Acquired Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Community-Acquired Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Community-Acquired Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Community-Acquired Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Community-Acquired Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Community-Acquired Infections Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Community-Acquired Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Community-Acquired Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Community-Acquired Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Community-Acquired Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Community-Acquired Infections Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Community-Acquired Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Community-Acquired Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Community-Acquired Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Community-Acquired Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Community-Acquired Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 32
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 33
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Panacea Biotec Limited, 2014* 34
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 35
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Tetraphase Pharmaceuticals Inc., 2014* 36
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by TaiGen Biopharmaceuticals Holdings Limited, 2014* 37
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Research & Development, LLC, 2014* 38
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Dong Wha Pharma Co., Ltd., 2014* 39
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Cubist Pharmaceuticals, Inc., 2014* 40
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Belpharma S.A., 2014* 41
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Hanyang University Medical Center, 2014* 42
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Ewha Womans University, 2014* 43
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Kyungpook National University, 2014* 44
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Katholieke Universiteit Leuven, 2014* 45
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Rennes University Hospital, 2014* 46
Community-Acquired Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Milan, 2014* 47

List of Figures
Community-Acquired Infections Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Community-Acquired Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Community-Acquired Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Community-Acquired Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Community-Acquired Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Community-Acquired Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Community-Acquired Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Community-Acquired Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Community-Acquired Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Community-Acquired Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Community-Acquired Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Community-Acquired Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Community-Acquired Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Community-Acquired Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Community-Acquired Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Community-Acquired Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Community-Acquired Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Community-Acquired Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Community-Acquired Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Community-Acquired Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Community-Acquired Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
GlobalData Methodology 72

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[市中感染(Community-Acquired Infections):世界の治験レビュー(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆